Lehrstuhl für Geburtshilfe und Frauenheilkunde

Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? (2018) Fasching P Journal article Complementary medicine in radiation oncology : German health care professionals' current qualifications and therapeutic methods (2018) Kessel KA, Klein E, Hack C, Combs SE Journal article Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study (2018) Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, et al. Journal article BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study (2018) Fasching P, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, et al. Journal article A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, et al. Journal article Desire to Have Children Among Transgender People in Germany: A Cross-Sectional Multi-Center Study (2018) Auer MK, Fuss J, Nieder TO, Briken P, Biedermann S, Stalla GK, Beckmann M, Hildebrandt T Journal article Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial (2018) Stevic I, Mueller V, Weber K, Fasching P, Karn T, Marme F, Schem C, et al. Journal article Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing (2018) Shimelis H, Laduca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, et al. Journal article The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer (2018) Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching P, et al. Journal article Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) (2018) Untch M, Von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P, Tesch H, et al. Journal article